Q3 2025 Myriad Genetics Inc Earnings Call Transcript
Key Points
- Myriad Genetics Inc (MYGN) reported a strong adjusted gross margin of 70.1% in the third quarter, reflecting operational efficiencies.
- The company saw significant volume growth in its MyRisk and oncology tests, with a 16% increase over the previous year.
- GeneSight volume grew by 8% year over year, indicating successful commercial focus on medium and higher volume accounts.
- The company is on track to launch its updated MyRisk test, which is expected to support strong growth in 2026 and beyond.
- Myriad Genetics Inc (MYGN) has secured positive coverage policies across nine states for GeneSight, enhancing its reimbursement landscape.
- Revenue for the third quarter was $205.7 million, a decline of 4% year over year, with average revenue per test down 7%.
- The company faced headwinds from UnitedHealthcare's policy change on GeneSight coverage, impacting revenue.
- There was a material $8.6 million prior-period contribution in the third quarter of 2024 that did not repeat, affecting year-over-year comparisons.
- The prenatal testing segment showed flat volume growth year over year, indicating challenges in regaining market share.
- The company is experiencing modest shifts in payer mix within its hereditary cancer portfolio, impacting average revenue per test.
Good day, and thank you for standing by. Welcome to the Myriad Genetics third-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Matt Scalo. Please go ahead.
Good afternoon, and welcome to the Myriad Genetics third-quarter 2025 earnings call. During the call, we will review the financial results we released today, and afterwards, we will host a Q&A session. Our quarterly earnings release was issued this afternoon on Form 8K and can be found on our website at investor.myriad.com.
I'm Matt Scalo, Senior Vice President of Investor Relations. On the call with me today are Sam Raha, our President and Chief Executive Officer; Ben Wheeler, our Chief Financial Officer; and Mark Verratti, our Chief Operating Officer. This call can be heard live via webcast at investor.myriad.com, and a recording will be archived in our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
